SyntekaBio Inc Cash Flow Conversion Efficiency
SyntekaBio Inc cash flow conversion efficiency. Based on the latest financial reports, SyntekaBio Inc (226330) has a cash flow conversion efficiency ratio of -0.098x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.77 Billion ≈ $-1.88 Million USD) by net assets (₩28.34 Billion ≈ $19.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SyntekaBio Inc (2017–2025)
Cash flow conversion efficiency of SyntekaBio Inc from 2017 to 2025. This chart illustrates how SyntekaBio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for SyntekaBio Inc for real-time trading data and today's change.
SyntekaBio Inc Cash Flow Conversion Ratio Explained
SyntekaBio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SyntekaBio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SyntekaBio Inc ranked by their cash flow conversion efficiency. Also see how much is SyntekaBio Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kiang Huat Sea Gull Trading Frozen Food Public Company Limited
BK:CHOTI
|
0.084x |
|
HM Inwest S.A.
WAR:HMI
|
0.164x |
|
Crookes Brothers Ltd
JSE:CKS
|
-0.038x |
|
Builders Capital Mortgage Corp
V:BCF
|
N/A |
|
New Bubbleroom Sweden AB
ST:BBROOM
|
0.097x |
|
Adler Group SA
F:ADJ
|
-0.053x |
|
Linius Technologies Ltd
AU:LNU
|
0.364x |
|
Zepp Health Corp
NYSE:ZEPP
|
0.416x |
Annual Cash Flow Conversion Efficiency for SyntekaBio Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of SyntekaBio Inc from 2017 to 2025. Review SyntekaBio Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩31.78 Billion ≈ $21.54 Million |
₩-10.65 Billion ≈ $-7.22 Million |
-0.335x | +20.46% |
| 2024-12-31 | ₩24.94 Billion ≈ $16.90 Million |
₩-10.51 Billion ≈ $-7.12 Million |
-0.421x | -62.87% |
| 2023-12-31 | ₩31.23 Billion ≈ $21.16 Million |
₩-8.08 Billion ≈ $-5.47 Million |
-0.259x | +4.38% |
| 2022-12-31 | ₩31.46 Billion ≈ $21.32 Million |
₩-8.51 Billion ≈ $-5.77 Million |
-0.271x | -23.73% |
| 2021-12-31 | ₩27.63 Billion ≈ $18.72 Million |
₩-6.04 Billion ≈ $-4.09 Million |
-0.219x | -94.57% |
| 2020-12-31 | ₩41.54 Billion ≈ $28.15 Million |
₩-4.67 Billion ≈ $-3.16 Million |
-0.112x | -57.95% |
| 2019-12-31 | ₩46.11 Billion ≈ $31.25 Million |
₩-3.28 Billion ≈ $-2.22 Million |
-0.071x | +95.06% |
| 2018-12-31 | ₩1.64 Billion ≈ $1.11 Million |
₩-2.37 Billion ≈ $-1.60 Million |
-1.441x | -261.66% |
| 2017-12-31 | ₩-2.79 Billion ≈ $-1.89 Million |
₩-2.49 Billion ≈ $-1.69 Million |
0.891x | -- |
About SyntekaBio Inc
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, di… Read more